|Bid||54.00 x 100|
|Ask||57.81 x 100|
|Day's Range||54.46 - 54.55|
|52 Week Range||53.56 - 56.19|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.12%|
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, announced today that it has closed an underwritten public offering of 1,500,000 American Depositary Shares ("ADS"), each ADS representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each), at a price to the public of $6.00 per ADS. In connection with the public offering, the underwriters exercised in full their over-allotment option to purchase an additional 166,667 shares of common stock at the public offering price, less the underwriting discount. As a result, the total public offering size was 1,666,667 shares, and the gross proceeds from the public offering were $10 million, before deducting underwriting discounts and offering expenses.
BiondVax Pharmaceuticals Ltd. (BVXV) (BVXV.TA), a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced that it intends to offer for sale its American Depositary Shares ("ADS"), each representing forty (40) of its ordinary shares which are listed on the Tel Aviv Stock Exchange (at NIS 0.0000001 par value each). All of the ADSs in the offering are being offered by BiondVax. The offering is subject to market conditions and there can be no assurance as to whether the offering may be completed, or as to the actual size or terms of the offering.
Europe's sovereign and corporate bonds, with high yields below 2.5%, are equally susceptible to pressure, according to Peter Boockvar, chief market analyst at The Lindsey Group based in Fairfax, VA. With the euro strengthening by 1.4% against the U.S. dollar this week, maintaining a value of 1.20, Boockvar writes in his daily morning missive today: "The strangest behavior in markets yesterday was the rip higher in the euro after European Central Bank President Mario Draghi’s press conference at the same time European sovereign bonds spiked up in price and down in yields. The euro today is holding its gains and advancing some more from yesterday’s close while European yields are rising and getting back some of what it lost yesterday after a Reuters story this morning that said: 'European Central Bank policymakers meeting on Thursday were in broad agreement that their next step will be reducing their bond purchases and discussed 4 options, 2 sources with direct knowledge of the discussion said.' They talked about to what extent to cut the monthly buys at the same time maybe extending the deadline.